Medicine and Dentistry
Acute Coronary Syndrome
19%
Acute Heart Infarction
26%
All Cause Mortality
10%
Angiography
22%
Apoplexy
12%
Atrial Fibrillation
11%
Bleeding
10%
Cardiogenic Shock
55%
Cardiovascular System
14%
Cause of Death
10%
Cohort Analysis
11%
Coronary Angiography
26%
Coronary Artery
14%
Coronary Artery Disease
35%
COVID-19
20%
Diabetes
36%
Diabetes Mellitus
37%
Disease
15%
Drug-Eluting Stent
56%
Everolimus
30%
Fractional Flow Reserve
19%
Hazard Ratio
37%
Heart Death
19%
In-Stent Restenosis
11%
Intravascular Ultrasound
36%
Ischemic Heart Disease
13%
Major Adverse Cardiac Event
16%
Myocardial Infarction
73%
Non ST Segment Elevation Myocardial Infarction
19%
Noninferiority Trial
10%
Odds Ratio
15%
Optical Coherence Tomography
36%
Out of Hospital Cardiac Arrest
13%
Paclitaxel
12%
Patient with Diabetes
24%
Percutaneous Coronary Intervention
100%
Primary Percutaneous Coronary Intervention
40%
Randomized Controlled Trial
9%
Rapamycin
76%
Restenosis
11%
Revascularization
41%
ST Segment Elevation Myocardial Infarction
92%
Stable Angina Pectoris
13%
Stenosis
12%
Stent Thrombosis
44%
Target Lesion
21%
Target Lesion Revascularization
20%
Thorax Pain
9%
Umirolimus
32%
Zotarolimus
22%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
9%
Acute Heart Infarction
24%
Adverse Event
5%
All Cause Mortality
11%
Antiplatelet
10%
Atrial Fibrillation
7%
Biological Marker
6%
Bleeding
8%
Brain Ischemia
8%
Cardiogenic Shock
33%
Cardiovascular Disease
15%
Cardiovascular Risk
9%
Cause of Death
7%
CD34 Antibody
9%
Cerebrovascular Accident
12%
Clopidogrel
7%
Cohort Study
9%
Congestive Heart Failure
6%
Coronary Artery Atherosclerosis
6%
Coronary Artery Disease
38%
Diabetes Mellitus
23%
Disease
19%
Everolimus
20%
Heart Death
23%
Heart Infarction
79%
In-Stent Restenosis
5%
Ischemic Heart Disease
15%
Major Adverse Cardiac Event
11%
Mortality Rate
6%
Non ST Segment Elevation Myocardial Infarction
11%
Noninferiority Trial
11%
Observational Study
5%
Out of Hospital Cardiac Arrest
10%
Paclitaxel
7%
Placebo
9%
Randomized Clinical Trial
8%
Randomized Controlled Trial
5%
Rapamycin
61%
ST Segment Elevation Myocardial Infarction
62%
Stable Angina Pectoris
10%
Stenosis
8%
Stent Thrombosis
46%
Umirolimus
34%
Zotarolimus
9%
Nursing and Health Professions
Acute Heart Infarction
7%
Cardiogenic Shock
12%
Clinical Outcome
12%
Computed Tomographic Angiography
5%
Confidence Interval
16%
Coronary Angiography
13%
Coronary Artery Disease
9%
Diabetes Mellitus
8%
Drug Eluting Coronary Stent
12%
Hazard Ratio
7%
Heart Infarction
11%
Patient with Diabetes
7%
Percutaneous Coronary Intervention
27%
Rapamycin
11%
Revascularization
13%
ST Segment Elevation Myocardial Infarction
21%
Stable Angina Pectoris
5%
Stent
19%
Stent Thrombosis
5%
Umirolimus
6%
